Hisamitsu Pharmaceutical Co (TSE:4530) Debt-to-Equity : 0.00 (As of Nov. 2023)

View and export this data going back to 1962. Start your Free Trial

What is Hisamitsu Pharmaceutical Co Debt-to-Equity?

Hisamitsu Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was 円1,071 Mil. Hisamitsu Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was 円95 Mil. Hisamitsu Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Nov. 2023 was 円269,082 Mil. Hisamitsu Pharmaceutical Co's debt to equity for the quarter that ended in Nov. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Hisamitsu Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

TSE:4530' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.01 Max: 0.01
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of Hisamitsu Pharmaceutical Co was 0.01. The lowest was 0.01. And the median was 0.01.

TSE:4530's Debt-to-Equity is ranked better than
99.88% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs TSE:4530: 0.01

Hisamitsu Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for Hisamitsu Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hisamitsu Pharmaceutical Co Debt-to-Equity Chart

Hisamitsu Pharmaceutical Co Annual Data

Trend

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Feb23

Feb24

Debt-to-Equity

Get a 7-Day Free Trial

0.01

Hisamitsu Pharmaceutical Co Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Debt-to-Equity	Get a 7-Day Free Trial															0.01	0.01	-	-	0.01

Competitive Comparison of Hisamitsu Pharmaceutical Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hisamitsu Pharmaceutical Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Hisamitsu Pharmaceutical Co's Debt-to-Equity falls into.

Hisamitsu Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Hisamitsu Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Feb. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1421	+	679)	/	264871
	=	0.01

Hisamitsu Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Nov. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1071	+	95)	/	269082
	=	0.00

Hisamitsu Pharmaceutical Co (TSE:4530) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Hisamitsu Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Hisamitsu Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Hisamitsu Pharmaceutical Co (TSE:4530) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hisamitsu Pharmaceutical Co Inc (TSE:4530) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

HPX:Germany

Address

408 Tashiro Daikan-machi, Tosu, Saga, JPN, 841-0017

Website

http://www.hisamitsu.co.jp

Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.

Hisamitsu Pharmaceutical Co (TSE:4530) Headlines

No Headlines